A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn’t yet shown the health impacts of cycling on and off the drugs.
GLP-1
Posted inNPR
What does a ‘GLP-1 Friendly’ diet look like? We asked nutritionists
Big food companies are starting to market to people on the powerful new obesity meds with labels that say “GLP-1 Friendly.” Nutritionists help us decode that message.
Posted inNPR
Using GLP-1s to maintain a normal weight? There are benefits and risks
Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric surgery to keep pounds from creeping back. Others may just want to lose a few pounds.
Posted inNPR
GLP-1 obesity drugs can complicate life for people with disordered eating
Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders.
Posted inNPR
GLP-1 drugs don’t work for everyone. But personalized obesity care in the future might
As doctors learn why GLP-1s don’t work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now.
Posted inNPR
5 things to know about the new obesity pills that are on the way
Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.
Posted inNPR
Advice for trying GLP-1 drugs for weight loss from a doctor who’s been there
Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with pitfalls. Here’s his tips for how to use them successfully.
Posted inNPR
I quit Ozempic and embraced feeling healthy over striving for thinness
Taking the drug made one writer feel so sick she quit and focused on healthy habits instead of her body size. Turns out, 65% of people using GLP-1 drugs for weight loss quit within a year.
Posted inNPR
When online weight-loss drugs are too good to be true
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy of the weight-loss medicines it mailed to patients.
Posted inNPR
Weight-loss drugs like Wegovy may help stave off some cancers
Several new studies find promising evidence that the GLP-1 class of drugs may have a cancer-preventive effect, especially for cancers linked to obesity.
